Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691482 · ClinicalTrials.gov registry record · Phase 4
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT01691482 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 56 participants.
The verdict
NCT01691482, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and when used in combination in subjects with COPD.
Interventions
- DRUG Albuterol/salbutamol
- DRUG Ipratropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-07-23 |
| Est. Completion | 2012-10-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691482
The ClinicalTrials.gov registry entry for NCT01691482 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albuterol/salbutamol is the first listed.
NCT01691482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01691482 about?
NCT01691482 is a clinical study titled "A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium". The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and when used in combination in subjects with COPD.
What is the current status of trial NCT01691482?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2012-07-23. Estimated completion is 2012-10-22.
What interventions are being tested in trial NCT01691482?
The interventions under investigation include: Albuterol/salbutamol (DRUG), Ipratropium (DRUG).
Who is sponsoring clinical trial NCT01691482?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.